

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

A. FURTHER INFORMATION ABOUT OUR GROUP

1. Incorporation

Our Company was registered as a limited liability company on November 10, 2017. On November 21, 2025, our Company was converted into a joint stock limited company under the laws of the PRC. As of the Latest Practicable Date, the registered capital of the Company was RMB37,278,840.

Our principal place of business in Hong Kong is at Room 1901, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong. Our Company was registered as a non-Hong Kong company under Part 16 of the Companies Ordinance on December 15, 2025. Ms. Leung Chi Ching has been appointed as the authorized representative of our Company for the acceptance of service of process in Hong Kong. The address for service of process is Room 1901, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong.

As our Company was incorporated in the PRC, its operations are subject to the relevant laws and regulations of the PRC. A summary of the relevant aspects of laws and regulations of the PRC and the Articles of Association is set out in “Regulatory Overview” in this document and Appendix V to this document, respectively.

2. Changes in Share Capital

Save as disclosed in “History, Development and Corporate Structure,” there has been no change in the share capital of our Company within the two years immediately preceding the date of this document.

3. Changes in Share Capital of our Subsidiaries

A summary of the corporate information and the particulars of our subsidiaries are set out in note 34 to the Accountants’ Report as set out in Appendix I to this Document.

On April 19, 2024, the registered capital of the Lynk Shaoxing was increased from RMB60 million to RMB96.6 million; on February 14, 2025, the registered capital was increased from RMB96.6 million to RMB108.6 million; and on October 31, 2025, the registered capital was further increased from RMB108.6 million to RMB133.6 million.

Save as disclosed above, there has been no changes in the share capital of our Subsidiaries during the two years immediately preceding the date of this Document. For details of our subsidiaries, please see “History, Development and Corporate Structure – Our Subsidiaries”.

4. Resolutions of our Shareholders

On November 27, 2025 and February 28, 2026, resolutions of our Company were passed by the Shareholders that, among other things, conditional upon the satisfaction (or, if applicable, waiver) of the conditions set out in “Structure of the [REDACTED] – Conditions of the [REDACTED]” and pursuant to the terms set out therein:

- (a) the [REDACTED] by the Company of H Shares with a nominal value of RMB[REDACTED] each and such H Shares be [REDACTED] on the Hong Kong Stock Exchange;
- (b) the number of H shares to be [REDACTED] shall be no more than [REDACTED]% of the total issued share capital of our Company as enlarged by the [REDACTED];

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

- (c) authorization of the Board or its authorized individual to handle all matters relating to, among other things, the [REDACTED], the [REDACTED] and the [REDACTED] of H Shares on the Hong Kong Stock Exchange;
- (d) subject to the completion of the [REDACTED], the conditional adoption of the revised Articles of Association, which shall become effective on the [REDACTED]; and
- (e) the subdivision of the Shares with a nominal value of RMB1.00 each on a one-for-four basis immediately prior to the [REDACTED], and taking into account the Share Subdivision, the issuance of H Shares with a nominal value of RMB0.25 each and such H Shares being [REDACTED] on the Stock Exchange.

B. FURTHER INFORMATION ABOUT OUR BUSINESS

1. Summary of Material Contracts

We have entered into the following contracts (not being contracts entered into in the ordinary course of business) within the two years immediately preceding the date of this document that are or may be material:

- (a) the [REDACTED].

2. Intellectual Property Rights

Trademarks

As of the Latest Practicable Date, we had registered the following trademarks, which we consider to be material to our business:

No.	Trademark	Place of Registration	Registered Owner	Class	Registration Number	Expiry Date (yyyy.mm.dd)
1.		PRC	Our Company	44	31652025	2029.05.27
2.		PRC	Our Company	5	31640188	2029.11.06
3.		PRC	Our Company	44	31656541	2029.05.27
4.		PRC	Our Company	42	88269083	2036.04.20
5.		PRC	Our Company	5	88269080	2036.04.20

Patents

As of the Latest Practicable Date, we had registered the ownership of and/or had the right to use the following patents which we consider to be or may be material to our business:

No.	Patent Name	Patentee	Place of Registration	Patent Number	Application Date (yyyy.mm.dd)
1.	A crystalline form, preparation method, and application of a pyrazolyl-amino-pyrimidinyl derivative (一種吡唑基-氨基-嘧啶基衍生物的晶型、製備方法及應用)	Our Company	PRC	2023105702936	2023.05.19

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Patent Name	Patentee	Place of Registration	Patent Number	Application Date (yyyy.mm.dd)
2.	A nitrogen-containing heterocyclic compound and its application (一種含氮雜環化合物及其應用)	Our Company	PRC	2022800869876	2022.12.28
3.	Benzamide of pyrazolyl-amino-pyrimidinyl derivatives and their compositions and methods (吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其組合物和方法)	Our Company	PRC	2019800761412	2019.12.16
4.	A pharmaceutical composition, topical formulation, and its preparation method and application (一種藥物組合物、外用製劑及其製備方法、應用)	Our Company	PRC	2023105930913	2023.05.24
5.	A sulfonamide compound and its application (一種磺醯胺類化合物及其應用)	Our Company	PRC	2023107956104	2023.06.30
6.	Phenyl ether and aniline of pyrazolyl-amino-pyrimidinyl derivatives and their compositions and methods (吡唑基-氨基-嘧啶基衍生物的苯醚和苯胺及其組合物和方法)	Our Company	PRC	2020800260110	2020.04.08
7.	Tricyclic Janus kinase 1 (JAK1) inhibitor and its compositions and methods (三環JANUS激酶1抑制劑及其組合物和方法)	Our Company	PRC	2019800708336	2019.11.01
8	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof	Our Company	Australia	AU2024201125	2019.12.16
9	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof	Our Company	Australia	AU2024201128	2019.12.16

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Patent Name	Patentee	Place of Registration	Patent Number	Application Date (yyyy.mm.dd)
10	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof	Our Company	Australia	AU2019399939	2019.12.16
11	Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof	Our Company	Australia	AU2019372677	2019.11.01
12	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof (吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其組合物和方法)	Our Company	Hong Kong (PRC)	HK62022045998.1	2019.12.16
13	Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof (三環JANUS激酶1抑制劑及其組合物和方法)	Our Company	Hong Kong (PRC)	HK62022046775.2	2019.11.01
14	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof (吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其組合物和方法)	Our Company	Macau (PRC)	MOJ008803	2019.12.16
15	A sulfonamide compound and its applications (一種磺酰胺類化合物及其應用)	Our Company	Macau (PRC)	MOJ008348	2023.06.30
16	Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof (三環JANUS激酶1抑制劑及其組合物和方法)	Our Company	Macau (PRC)	MOJ008169	2019.11.01
17	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof (吡唑基-氨基-嘧啶基衍生物的苯甲酰胺及其組合物和方法)	Our Company	Taiwan (PRC)	TW113122616	2019.12.13

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Patent Name	Patentee	Place of Registration	Patent Number	Application Date (yyyy.mm.dd)
18	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof (吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其組合物和方法)	Our Company	Taiwan (PRC)	TW113122615	2019.12.13
19	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof (吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其組合物和方法)	Our Company	Taiwan (PRC)	TW108145807	2019.12.13
20	Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof (三環 JANUS 激酶1 抑制劑及其組合物和方法)	Our Company	Taiwan (PRC)	TW108139784	2019.11.01
21	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof (Б Е Н З А М И Д Ы П Р О И З В О Д Н Ы Х П И Р А З О Л И Л - А М И Н О - П И Р И М И Д И Н И Л А , К О М П О З И Ц И И Н А И Х О С Н О В Е И С П О С О Б Ы П Р И М Е Н Е Н И Я)	Our Company	Eurasian Economic Community	EA202191188	2019.12.16
22	Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof	Our Company	EU	EP19878002.5	2019.11.01
23	Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof (TRICYCLISCHE JANUS-KINASE-1- INHIBITOREN UND ZUSAMMENSETZUNGEN UND VERFAHREN DAFÜR)	Our Company	Switzerland/ Liechtenstein	EP19878002	2019.11.01

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Patent Name	Patentee	Place of Registration	Patent Number	Application Date (yyyy.mm.dd)
24	Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof (Inhibidores tricíclicos de la Janus cinasa 1, y composiciones y procedimientos de los mismos)	Our Company	Spain	ES2019878002T	2019.11.01
25	TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF	Our Company	The U.K.	EP19878002	2019.11.01
26	Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof	Our Company	Ireland	EP19878002	2019.11.01
27	TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF	Our Company	Norway	NO3856742	2019.11.01
28	Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof (TRÓJCYKLICZNE INHIBITORY KINAZY JANUSOWEJ 1 ORAZ ICH KOMPOZYCJE I SPOSOBY)	Our Company	Poland	PL2019878002T	2019.11.01
29	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof	Our Company	Israel	IL283968	2019.12.16
30	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof	Our Company	India	IN202117028370	2019.12.16
31	Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof	Our Company	India	IN202127023994	2019.11.01

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Patent Name	Patentee	Place of Registration	Patent Number	Application Date (yyyy.mm.dd)
32	Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof (三環系ヤヌスキナーゼ1阻害剤ならびにその組成物および方法)	Our Company	Japan	JP2021525022	2019.11.01
33	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof (ピラゾリル-アミノ-ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法)	Our Company	Japan	JP2021530299	2019.12.16
34	Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof (트리사이클릭 야누스 키나제 1 억제제 및 이의 조성물 및 방법)	Our Company	Korea	KR1020217013443	2019.11.01
35	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof (BENZAMIDAS DE DERIVADOS DE PIRAZOLIL-AMINO-PIRIMIDINILO Y COMPOSICIONES Y MÉTODOS DE LAS MISMAS)	Our Company	Mexico	MX2021006866	2019.12.16
36	Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof (INHIBIDORES DE CINASA DE JANUS 1 TRICICLICOS Y COMPOSICIONES Y MÉTODOS DE LOS MISMOS)	Our Company	Mexico	MX2021004517	2019.11.01

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Patent Name	Patentee	Place of Registration	Patent Number	Application Date (yyyy.mm.dd)
37	Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof (ТРИЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ЯНУС-КИНАЗЫ 1, ИХ КОМПОЗИЦИИ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ)	Our Company	Russia	RU2021109473	2019.11.01
38	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof	Our Company	Saudi Arabia	SA521422251	2019.12.16
39	Tricyclic Janus Kinase 1 Inhibitors, and Compositions and Methods Thereof	Our Company	Saudi Arabia	SA521421881	2019.11.01
40	Crystal form of pyrazolyl-amino-pyrimidinyl derivative, and preparation method therefor and use thereof	Our Company	Singapore	SG11202308192R	2023.05.19
41	Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof	Our Company	Singapore	SG11202103694U	2019.11.01
42	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof	Our Company	The U.S.	US17/684030	2018.12.14
43	Crystal form of pyrazolyl-amino-pyrimidinyl derivative, and preparation method therefor and use thereof	Our Company	The U.S.	US18/495213	2023.05.19
44	TYK2 inhibitors and compositions and methods thereof	Our Company	The U.S.	US18/372417	2021.12.16
45	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof	Our Company	The U.S.	US18/372115	2018.12.14

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Patent Name	Patentee	Place of Registration	Patent Number	Application Date (yyyy.mm.dd)
46	Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof	Our Company	The U.S.	US18/244276	2018.12.14
47	Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof	Our Company	The U.S.	US17/289584	2019.11.01
48	Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof	Our Company	The U.S.	US18/377741	2019.04.08
49	Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof	Our Company	The U.S.	US18/244281	2018.12.14
50	Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof	Our Company	The U.S.	US18/217009	2019.11.01
51	Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof	Our Company	The U.S.	US18/217037	2019.11.01
52	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof (Benzamit của dẫn xuất pyrazolyl-amino-pyrimidinyl, và được phẩm bao gồm chúng)	Our Company	Vietnam	VN1202104190	2019.12.16

Domain Name

As of the Latest Practicable Date, we had registered the following internet domain names which we consider to be or may be material to our business:

No.	Domain Name	Registered Owner	Expiry Date (yyyy.mm.dd)
1.	lynkpharma.com	Our Company	2031.03.24
2.	lynkpharma.com.cn	Our Company	2032.06.10
3.	lynktherapeutics.com.cn	Our Company	2031.04.02

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Domain Name	Registered Owner	Expiry Date (yyyy.mm.dd)
4.	lynktherapeutics.cn	Our Company	2031.04.02
5.	lynktherapeutics.com	Our Company	2031.04.02
6.	lynktx.com.cn	Our Company	2031.04.02
7.	lynktx.cn	Our Company	2031.04.02
8.	lynktx.com	Our Company	2031.04.02

Save as the above, as of the Latest Practicable Date, there were no other intellectual property rights which were material to our business.

C. FURTHER INFORMATION ABOUT OUR DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

1. Particulars of Directors’ service contracts and appointment letters

We have entered into a service contract with each of our Directors which contains provisions in relation to, among others, term of service and termination. The service contracts may be renewed in accordance with our Articles of Association and the applicable rules. Save as disclosed in “Directors and Senior Management” and above, we have not entered into, and do not propose to enter into, any service contracts with any of our Directors in their respective capacities as Directors (excluding agreements expiring or determinable by any member of our Group within one year without payment of compensation other than statutory compensation).

2. Remuneration of Our Directors

Save as disclosed in “Directors and Senior Management” and “Appendix I – Accountants’ Report – Notes to The Historical Financial Information – Directors’ and Chief Executives’ emoluments”, none of our Directors received other remuneration or benefits in kind from our Company during the two years ended December 31, 2024, 2025 and the three months ended March 31, 2026.

3. Disclosure of Interests of Directors and Chief Executive of our Company

Save as disclosed below, immediately following the completion of the [REDACTED] (assuming that the [REDACTED] are not exercised), so far as our Directors are aware, none of our Directors or chief executive has any interests or short positions in our Shares, underlying Shares and debentures of our Company or its associated corporations (within the meaning of Part XV of the SFO) which will have to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he or she is taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to Section 352 of the SFO, to be recorded in the register referred to therein, or which will be required to be notified to our Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Companies contained in the Listing Rules.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

Interests in our Company

Name	Position	Nature of interest	Number of H Shares interested in following completion of the [REDACTED] ⁽¹⁾	Approximate percentage of shareholding in the total issued Shares immediately after the [REDACTED] ⁽²⁾
Dr. Wan	Chairman of the Board, executive Director and chief executive officer	Beneficial interest	[REDACTED]	[REDACTED]%
		Interest in controlled corporation ⁽³⁾⁽⁴⁾	[REDACTED]	[REDACTED]%
		Interest of a party to an agreement regarding interest in our Company ⁽⁵⁾	[REDACTED]	[REDACTED]%
Dr. Wang	Executive Director and chief scientific officer	Beneficial interest	[REDACTED]	[REDACTED]%
		Interest of a party to an agreement regarding interest in our Company ⁽⁵⁾	[REDACTED]	[REDACTED]%

Notes:

- (1) All interests stated are long position.
- (2) The calculation is based on the total number of [REDACTED] H Shares in [REDACTED] immediately following the completion of the [REDACTED] comprising [REDACTED] H Shares to be [REDACTED] upon conversion of the same number of Domestic Unlisted Shares and [REDACTED] H Shares to be [REDACTED] pursuant to the [REDACTED] (taking into account the Share Subdivision and assuming the [REDACTED] is not exercised.).
- (3) Dr. Wan holds approximately 65.51% of the partnership interest in Lingxin Partnership as general partner. As such, Dr. Wan is deemed to be interested in the [REDACTED] H Shares of the Company held by Lingxin Partnership under the SFO.
- (4) Dr. Wan and Dr. Vazquez hold 26.14% and 55.60% shareholding interests in Lynk Investment respectively. Pursuant to a voting agreement dated October 29, 2025 entered into between Dr. Wan and Dr. Vazquez, Dr. Vazquez entrusted the voting rights of all shares in Lynk Investment to Dr. Wan. As such, Dr. Wan is deemed to be interested in the [REDACTED] H Shares of the Company held by Lynk Investment under the SFO.
- (5) Dr. Wan, Dr. Wang, Lingxin Partnership, and Lynk Investment entered into two acting in concert agreements on June 30, 2021 and November 25, 2025 respectively, pursuant to which the parties agreed to act in concert in connection with their respective shareholdings in the Company (being [REDACTED] H Shares, [REDACTED] H Shares, [REDACTED] H Shares and [REDACTED] H Shares respectively immediately following the completion of the [REDACTED] and taking into account the Share Subdivision) and in the event of disagreement follow Dr. Wan’s voting directions. Therefore, each of Dr. Wan, Dr. Wang, Lingxin Partnership and Lynk Investment is deemed to be interested in the H Shares held by others under the SFO. See “Relationship with Our Single Largest Group of Shareholders – Our Single Largest Group of Shareholders” for further details.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

Disclosure of Interests of Substantial Shareholders

(a) Interests in our Company

Save as disclosed in “Substantial Shareholders” of this document, our Directors are not aware of any other person, not being a Director or chief executive of our Company, who have any interest or short position in the Shares or underlying Shares, which following completion of the [REDACTED], will fall to be disclosed to our Company under the provisions of Divisions 2 and 3 of Part XV of the SFO.

(b) Interests of substantial shareholders of other members of our Group

Our Directors are not aware of any persons who will, immediately following the completion of the [REDACTED], directly or indirectly, be interested in 10% or more of the [REDACTED] voting shares of any other member of our Group.

4. Disclaimers

(a) None of our Directors or any of the parties listed in “– E. Other Information – 5. Consents and Qualification of Experts” below is:

- (i) interested in our promotion, or in any assets which, within the two years immediately preceding the date of this document, have been acquired or disposed of by or leased to us, or are proposed to be acquired or disposed of by or leased to us;
- (ii) materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to our business;

(b) Save in connection with the [REDACTED] and the [REDACTED], none of the parties listed in “– E. Other Information – 5. Qualification of Experts” below:

- (i) is interested legally or beneficially in any shares in any member of our Group; or
- (ii) has any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for any securities in any member of our Group;

(c) None of our Directors or their close associates or any shareholders of our Company who to the knowledge of our Directors owns more than 5% of our issued share capital has any interest in our top five customers or suppliers.

D. SHARE INCENTIVE SCHEME

Our Company adopted an employee share incentive plan on June 30, 2021 (as amended) (“**Employee Share Incentive Plan**”), pursuant to which share awards may be granted to our eligible employees as an incentive to strengthen our competitive advantage in human resources and facilitate our strategic growth. As of the Latest Practicable Date, there were no outstanding share awards under the Employee Share Incentive Plan, and no further share awards will be granted pursuant to the Employee Share Incentive Plan.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

E. OTHER INFORMATION

1. Estate Duty

Our Directors have been advised that no material liability for estate duty under the PRC law is likely to fall on our Company or any of our subsidiaries.

2. Litigation

So far as our Directors are aware, no litigation or claim of material importance is pending or threatened against any member of our Group.

3. Joint Sponsors

The Joint Sponsors have made an application on our behalf to the Listing Committee for the [REDACTED] of, and permission to [REDACTED], our H Shares. All necessary arrangements have been made to enable the securities to be admitted into [REDACTED].

Each of the Joint Sponsors satisfy the independence criteria applicable to sponsors as set out in Rule 3A.07 of the Listing Rules.

Pursuant to the engagement letter entered into between the Company and the Joint Sponsors, we have agreed to pay each of the Joint Sponsors a fee of USD[REDACTED] to act as the sponsors of our Company in connection with the [REDACTED] on the Hong Kong Stock Exchange.

4. Preliminary Expenses

Our Company did not incur any material preliminary expenses.

5. Consents and Qualification of Experts

The following experts have each given and have not withdrawn their respective written consents to the issue of this Document with copies of their reports, letters, opinions or summaries of opinions (as the case may be) and the references to their names included herein in the form and context in which they are respectively included.

Name	Qualification
CITIC Securities (Hong Kong) Limited	A licensed corporation under the SFO to conduct Type 4 (advising on securities) and Type 6 (advising on corporate finance) regulated activities as defined under the SFO
CCB International Capital Limited	A licensed corporation under the SFO to carry on type 1 (dealing in securities), type 4 (advising on securities) and type 6 (advising on corporate finance) regulated activities as defined under the SFO
Deloitte Touche Tohmatsu	Certified Public Accountants and Registered Public Interest Entity Auditor
Tian Yuan Law Firm	Legal Advisor to our Company as to PRC laws
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.	Industry consultant

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

6. Promoter

The promoters of our Company comprised all of the 33 then shareholders of our Company as at November 21, 2025 before our conversion into a joint stock limited liability company. Within the two years immediately preceding the date of this document, no cash, securities or benefit has been paid, allotted or given, or is proposed to be paid, allotted or given to the promoters named above in connection with the [REDACTED] or the related transactions described in this document.

7. Binding Effect

This document shall have the effect, if an application is made in pursuance hereof, of rendering all persons concerned bound by all the provisions (other than the penal provisions) of sections 44A and 44B of the Companies Ordinance so far as applicable.

8. Bilingual Document

The English language and Chinese language versions of this document are being published separately in reliance upon the exemption provided by section 4 of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

9. Compliance Adviser

Our Company has appointed Red Sun Capital Limited as our compliance adviser in compliance with Rule 3A.19 of the Listing Rules.

10. No Material Adverse Change

The Directors confirm that there has been no material change in our financial or [REDACTED] position since March 31, 2026, the end of the period reported on the Accountants' Report included in Appendix I to this document.

11. Miscellaneous

- (a) Within the two years immediately preceding the date of this document:
 - (i) no share or loan capital or debenture of our Company or any of our subsidiaries has been issued or agreed to be issued or is proposed to be issued for cash or as fully or partly paid other than in cash or otherwise; and
 - (ii) no commissions, discounts, brokerages or other special terms have been granted or agreed to be granted in connection with the issue or sale of any share or loan capital of our Company or any of our subsidiaries.
- (b) Save as disclosed in this document:
 - (i) there are no founder, management or deferred shares nor any debentures in our Company or any of our subsidiaries;
 - (ii) no share or loan capital or debenture of our Company or any of our subsidiaries is under option or is agreed conditionally or unconditionally to be put under option;
 - (iii) there are no arrangements under which future dividends are waived or agreed to be waived;

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

- (iv) there are no procedures for the exercise of any right of pre-emption or transferability of subscription rights;
- (v) there have been no interruptions in our business which may have or have had a significant effect on our financial position in the last 12 months;
- (vi) there are no restrictions affecting the remittance of profits or repatriation of capital by us into Hong Kong from outside Hong Kong;
- (vii) no part of the equity or debt securities of our Company, if any, is currently listed on or dealt in on any stock exchange or trading system, and no such listing or permission to list on any stock exchange other than the Stock Exchange is currently being or agreed to be sought; and
- (viii) our Company has no outstanding convertible debt securities or debentures.